Clinical Trial Search

Primary: Objective Response Rate (ORR) — 18.3; 15.7 Percentage of participants

Primary: Opioid Requirement at 24 Hours Post-randomization — 38; 202 morphine milligram equivalents

Primary: Number of Participants Transferred to Intensive Care Unit (ICU) — 4 Participants

Primary: Number of Participants With Adverse Events (AEs). — 1; 3; 2; 0 Participants

Primary: Score on the WHO 11-point Ordinal Scale for Clinical Improvement at 14 Days — 2; 2 score on a scale

Primary: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) — 3; 4; 5; 2 Participants

Primary: Number of Patients With Improvement in Global Rating of Smell Change — 4; 3 Participants

Primary: Incidence of Adverse Events in Placebo and Active Treatment Groups — 25; 27; 25; 23 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 6; 8 Participants

Primary: Safety of In-hospital Thromboprophylaxis as Assessed by Number of Participants With ISTH-defined Clinically-relevant Bleeding Events During Hospitalization — 0…

Primary: The Percent Change in Serum GGT. — -4.9; -19; -8.4 percent change

Primary: Change From Baseline to 12 Weeks in Systolic Ambulatory Blood Pressure in the Chlorthalidone Group Compared to Placebo. — -11.0; -0.5 mm Hg

Primary: Incidence of Treatment Emergent Adverse Event (TEAE) Adjusted by Duration of Participant Exposure to Treatment — 76.00 no. of new events per 100 subject-years

Primary: Worst Pain as Measured by the Brief Pain Inventory (BPI) at 1 Year — 0; 0 score on a scale — p=0.68

Primary: Percentage of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 33.3; 16.7 Percentage of Participants